<DOC>
	<DOCNO>NCT00338741</DOCNO>
	<brief_summary>The objective establishing Rebif® Pregnancy Registry collect prospective outcome data woman United States Canada expose Rebif® pregnancy . The primary end point rate spontaneous abortion expose pregnancy . This rate compare rate spontaneous abortion patient Multiple Sclerosis ( MS ) whose pregnancy expose interferon-beta manner consistent FDA August 2002 Guidance Industry : Establishing Pregnancy Exposure Registries</brief_summary>
	<brief_title>Rebif® Pregnancy Registry</brief_title>
	<detailed_description>This study post-approval commitment follow Rebif®-exposed pregnancy compare non-Rebif® exposed pregnancy evaluate rate spontaneous abortion , fetal abnormality pregnancy relate health outcome .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Rebif®Exposed Group For prospective followup , woman United States Canada shall eligible enrollment Rebif® Pregnancy Registry subject : They pregnant . They receive Rebif® treatment Multiple Sclerosis ( MS ) within one week time conception . The outcome pregnancy previously evaluate diagnostic method ultrasound . However , since ultrasound technique often use early stage confirm pregnancy , patient evaluate ultrasound purpose confirm pregnancy shall eligible enrollment Registry . The use ultrasound inference could make outcome patient 's pregnancy report case report form . Following enrollment Registry , diagnostic test may perform time pregnancy . They use Copaxone® treatment MS within previous three month expose Novantrone® , Imuran® , Cytoxan® , Tysabri® methotrexate time . Patients expose investigational product procedure within previous year may enrol discretion Medical Director . The enrol physician contact Serono 's authorized agent , company call Registrat , 8669973243 request review patient 's situation . Interferonbeta Not Exposed Comparison Group Women MS live United States Canada eligible comparison group : They pregnant . The outcome pregnancy previously evaluate diagnostic method ultrasound . However , since ultrasound technique often use early stage confirm pregnancy , patient evaluate ultrasound purpose confirm pregnancy shall eligible enrollment Registry . The use ultrasound inference could make outcome patient 's pregnancy report case report form . Following enrollment Registry , diagnostic test may perform time pregnancy . They receive interferonbeta within 90 day conception . They use Copaxone® treatment MS within previous three month expose Novantrone® , Imuran® , Cytoxan® , Tysabri® methotrexate time . Patients expose investigational product procedure within previous year may enrol discretion Medical Director . The enrol physician contact Serono 's authorized agent , company call Registrat , 8669973243 request review patient 's situation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>